Peripheral Neuropathies
Carbon disulfide neuropathy
Jun. 11, 2026
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Amiodarone neuropathy
- Updated 07.31.2025
- Released 09.21.2001
- Expires For CME 07.31.2028
Amiodarone neuropathy
Introduction
Overview
The author reviews the clinical neurotoxicity of the antiarrhythmic agent amiodarone, an amphiphilic drug that forms intralysosomal lipid complexes in multiple tissues. The most common amiodarone-related neurotoxicities are tremor, ataxia, and peripheral neuropathy; more infrequent neurotoxicities include myopathy, optic neuropathy, basal ganglia dysfunction, encephalopathy, and pseudotumor cerebri. The neuropathy is usually a subacute to chronic sensorimotor polyneuropathy with axonal, demyelinating, or mixed features.
Key points
|
• The most common amiodarone-related neurotoxicities are tremor, ataxia, and peripheral neuropathy; more infrequent neurotoxicities include myopathy, optic neuropathy, basal ganglia dysfunction, encephalopathy, and pseudotumor cerebri. | |
|
• The neuropathy is usually a subacute to chronic sensorimotor polyneuropathy with axonal, demyelinating, or mixed features. | |
|
• Amiodarone is an amphiphilic drug that forms intralysosomal lipid complexes in multiple tissues. |
Historical note and terminology
Amiodarone is a di-iodinated benzofuran derivative initially developed in the 1960s as an antianginal agent; it was later used as a cardiac antiarrhythmic agent in the management of supraventricular and ventricular arrhythmias. It is approved in the United States for the treatment of refractory and life-threatening ventricular arrhythmias. Like bretylium and sotalol, it is a class III antiarrhythmic agent and shares the capacity to prolong the duration of action potentials and refractoriness in Purkinje fibers and ventricular muscle (53). Neurotoxic side effects were first described in the 1970s and consist principally of a sensorimotor polyneuropathy, tremor, and ataxia and more infrequently, myopathy, optic neuropathy, basal ganglia dysfunction, encephalopathy, and pseudotumor cerebri. Dronedarone, a drug approved in 2009 for atrial fibrillation, is structurally related to amiodarone, but noniodinated, and it may have a more favorable overall safety profile (15).
Clinical manifestations
Presentation and course
|
• The neuropathy of amiodarone toxicity is a subacute to chronic sensorimotor polyneuropathy with distal predominance. | |
|
• Tremor is the most frequent neurotoxic side effect of amiodarone. |
The clinical presentation of neuropathy related to chronic amiodarone therapy is that of a symmetric, subacute to chronic, sensorimotor polyneuropathy with distal predominance; some reports note proximal weakness, and occasionally the neuropathy is predominantly motor (39; 32; 38; 12; 47; 03; 22; 01; 20; 48). The evolution may be rapid, mimicking Guillain-Barré syndrome (48). There is a glove-stocking loss of all sensory modalities, depressed reflexes, and an ataxic gait. There is one report of autonomic neuropathy (35). In terms of acute toxicity, a case of acute suicidal self-administration of 8 grams of oral amiodarone resulted in profuse sweating, prolonged QT interval, and sinus bradycardia but no untoward effects over 3 months of follow-up (04).
A few patients have developed a clinical myopathy, with or without associated neuropathy, with a proximal pattern of weakness and occasionally myalgia (39; 11; 16; 20; 48). Dysphagia occurred in three of four cases in one series (21). Serum CK may be normal or elevated (21). One report describes a single patient with reversible acute severe diffuse muscle cramps after initiation of intravenous amiodarone therapy (55). An inadvertent intraarterial injection of amiodarone in one patient resulted in thrombotic occlusion at the injection site and a subsequent severe compartment syndrome of the arm (61).
Tremor with (or usually without) neuropathy is the most frequent neurotoxic side effect reported, occurring in 43% and 39% of patients in two large series (12; 45) and appearing early in the course of therapy. It is a 6 to 10 Hz action tremor, bilateral and symmetric, and clinically indistinguishable from essential tremor (12). Gait ataxia is also common, occurring in 7% and 37% of cases in these same series (12; 45). It is not always explainable based on neuropathy and is occasionally associated with limb ataxia and other findings clearly suggesting cerebellar dysfunction (12; 01; 30; 13; 27).
Optic neuropathy may occur and is usually characterized by insidious onset and slow progression of bilateral visual loss, usually associated with optic disc swelling (19; 36; 42; 33; 41; 46; 28; 59; 57; 40). Alternatively, the presentation may be acute or the localization retrobulbar (26).
Additional neurotoxicity, based on a handful of case reports, includes parkinsonian features of rest tremor, bradykinesia, or rigidity (60), other basal ganglia dysfunction including myoclonus, hemiballismus, and dyskinesia (45; 60), as well as encephalopathy with EEG slowing (45) and pseudotumor cerebri (10), all reversible with discontinuation of the drug. In a case series of 126 patients with idiopathic bilateral vestibulopathy, 12% had a history of preceding amiodarone treatment (23).
Prognosis and complications
Whether mild or severe, neuropathy tends to improve with lowering the dose or discontinuing the drug (38; 48), with an occasional exception resulting in persistent disability (03; 21). Improvement occurs over weeks to months.
Biological basis
|
• Amiodarone is an amphiphilic drug that forms intralysosomal lipid complexes in multiple tissues. | |
|
• Because of its long elimination half-life, recovery can be slow following discontinuation. | |
|
• As a potent inhibitor of the CYP3A4 isozyme of the cytochrome P450 enzyme system, concomitant use of amiodarone may potentiate the myotoxicity of statins. | |
|
• Electrodiagnostic studies of amiodarone-associated neuropathy may show axonal, demyelinating, or mixed features. | |
|
• Amiodarone is one of the few toxins that can be associated with a demyelinating neuropathy and mimic Guillain-Barre syndrome or chronic inflammatory demyelinating polyneuropathy, depending on the tempo. |
Etiology and pathogenesis
The neuropathy is toxic and related to the administration of amiodarone. Although the exact mechanism of amiodarone tissue toxicity is uncertain, a relationship to the diffuse and marked lipidosis is suspected. Like other amphiphilic drugs such as perhexiline maleate, amiodarone forms intralysosomal lipid complexes, leading to the observed inclusions in multiple tissues. An immunologic mechanism has been suggested to explain observations such as early onset toxicity, possible steroid responsiveness in pulmonary toxicity, and various immunologic perturbations (58). Studies in rat brain synaptosomes have suggested that neurotoxicity might be mediated by effects on ATPase activity or calcium homeostasis (50; 29). In a study utilizing an immortalized adult rat Schwann cell line, findings suggested that amiodarone-induced lysosomal storage accompanied by enhanced oxidative stress and impaired lysosomal degradation in Schwann cells might be the cause of peripheral nerve demyelination (43).
Oral amiodarone is poorly and slowly absorbed; bioavailability ranges from 22% to 86% (31; 04; 53). As it is highly lipophilic, distribution is extensive into tissues. Peak plasma concentrations occur about 5 to 6 hours after an oral dose. Metabolism occurs slowly in the liver; less than 1% is excreted unchanged in the urine. The plasma half-life is estimated to be about 25 to 60 days but may be as long as 100 days. The only metabolite is desethylamiodarone, which accumulates during long-term treatment with a plasma concentration that may exceed that of the parent compound; its pharmacologic activity is not well known. Long-term therapeutic effectiveness for arrhythmias is associated with an amiodarone plasma concentration of 1.0 to 2.5 µg/mL. Treatment is generally initiated with an oral loading dose of approximately 10 g in the first 1 to 2 weeks, followed by the recommended maintenance dose of 200 mg daily (63). Amiodarone increases the plasma concentration of phenytoin. Side effects with amiodarone are poorly correlated with serum levels. Although reports vary, some clearly suggest a relationship between toxicity and the dose and duration of treatment (31; 58). Because of its long elimination half-life, recovery can be slow following discontinuation. As a potent inhibitor of the CYP3A4 isozyme of the cytochrome P450 enzyme system, concomitant use of amiodarone may potentiate the myotoxicity of statins (54; 02; 52; 37). Grapefruit juice may enhance the toxicity of amiodarone by its effect on CYP 3A4 (07).
In animal studies, rats and mice fed large doses of amiodarone for up to 90 days develop dose-related weight loss, decreased motor activity, weakness, and tremor (18). Cytoplasmic lysosomal lipid inclusions are diffusely found in tissues but are excluded from regions with intact blood-brain and blood-nerve barrier. These are present in all cell types in autonomic and dorsal root ganglia, myenteric plexus, and centrally in the area postrema, choroid plexus, ocular tissues, and pituitary. Increased blood-nerve permeability by sciatic nerve crush results in short-lived appearance of inclusions but does not affect the rate of axonal regeneration. In another study, rats treated with amiodarone intraperitoneally at 20 mg/kg per day for up to 6 weeks developed motor incoordination and increased pain thresholds, suggesting the appearance of peripheral neuropathy (49). Amiodarone injected endoneurially into rat tibial nerve at low concentrations (25 µg/mL) produces acute electrophysiologic evidence of demyelination with conduction block and pathologic evidence of segmental demyelination (56). Higher concentrations result in increasingly severe axonal degeneration, suggesting that the different pathologic changes noted in human neuropathy may be related to variable blood-nerve barrier efficacy, leading to different drug concentrations in the nerve. Chronic amiodarone in mice also produces a myopathy with autophagic vacuolation and phospholipid inclusions; denervation induces necrosis of mainly type-2 fibers and a significant increase in amiodarone and desethylamiodarone concentrations in the muscle (17). Cytoplasmic lipid inclusions, similar to those in humans, can be reproduced experimentally in many ocular cell types of rats with local application or oral administration of amiodarone (09). ATP administered to rats may partially inhibit amiodarone-induced optic neuropathy (08). Desethylamiodarone alone, as well as its parent compound, can induce lipidosis in rat alveolar macrophages, suggesting that it too is active (51).
In humans, reports of nerve conduction studies and needle EMG vary from a predominant axonopathy with reduced amplitudes and distal denervation to prominent conduction slowing suggesting primary demyelination, to a mixed picture (39; 38; 47; 03; 22; 18; 48). Sural nerve biopsy specimens similarly show either predominant axonal degeneration affecting fibers of all sizes (39), predominant or almost pure demyelination (18), or a mixture (48). Numerous lysosomal inclusions are present in Schwann cells, axoplasm, fibroblasts, capillary endothelial and perithelial cells, and perineural cells (39; 32; 47; 18; 01; 48). In one reported case with peripheral neuropathy, concentrations of amiodarone and desethylamiodarone in a sural nerve biopsy were 80 times higher than in serum (22). Pathologic examination of retrobulbar optic nerve in a patient on amiodarone who was enucleated for melanoma demonstrated intracytoplasmic lamellar inclusions in large axons (36). Myopathic cases have shown myopathic EMG and muscle biopsy usually showing vacuolar changes, lipid inclusions, and marked accumulation of amiodarone and desethylamiodarone; occasionally, there is denervation atrophy (39; 11; 16; 20; 48). A few cases have shown a necrotizing myopathy (16; 21). Neuropathologic correlates of tremor and ataxia have not been reported, but a postmortem in a patient with amiodarone-induced liver cirrhosis and parkinsonism demonstrated amiodarone accumulation in the cerebral white matter and basal ganglia (24).
Epidemiology
The reported incidence of neurotoxicity is widely variable, ranging from 2.8% to 74% in large series (58; 44). The variability is likely related to several factors, including (1) varied dosages used, (2) difficulties in distinguishing amiodarone-related side effects from signs and symptoms of underlying illness in sick cardiac patients, (3) variable follow-up periods, and (4) different sensitivities of investigators to specific side effects. In many studies, peripheral neuropathy is correlated poorly with daily dose and total dose or treatment duration. Most reported cases are on moderate to large doses for months to years, but symptoms occur on as little as 200 mg per day with durations of 1 month, suggesting interindividual variability of amiodarone metabolism (47). The most recent study of amiodarone neurotoxicity utilizing the recommended 200 mg daily dose reported a cumulative incidence of 2.8%; the primary risk factor for neurotoxicity was duration of treatment (44). A large, retrospective, population-based cohort study in Taiwan showed a higher risk of optic neuropathy in patients treated with amiodarone, especially in males, and it was possibly associated with a longer duration of treatment but not a higher daily dose (14). In a MarketScan database study in 2018, the risk for peripheral neuropathy with the newer related antiarrhythmic dronedarone was not significantly different from other antiarrhythmics, including amiodarone (62).
Prevention
No specific agent is known to prevent amiodarone neurotoxicity. One study of grape seed proanthocyanidins suggested that they could protect against amiodarone-induced pulmonary toxicity in mice (06; 05). Although even low doses may eventuate in toxicity, most cases are related to larger doses over long periods, so limiting the dose and cutting back when symptoms or signs of toxicity appear is important. Although no specific information is available for amiodarone, by example from other neurotoxic agents, the presence of a preexisting neuropathy may be suspected to be a risk factor for developing severe neuropathy.
Differential diagnosis
Confusing conditions
The symptoms, signs, and electrophysiologic features are not specifically distinguishable from other toxic or nontoxic distal axonopathies. The temporal relationship between amiodarone administration and improvement with decreasing the dose or discontinuation should clarify the issue. In general, consideration of excluding other common causes of axonal polyneuropathy is probably prudent. Confusion with chronic inflammatory demyelinating polyneuropathy may arise in some cases where demyelinating electrophysiologic abnormalities are prominent.
Diagnostic workup
The neuropathy should be established by clinical examination and characterized electrophysiologically. The CSF shows normal or mildly elevated protein without pleocytosis (47). In most cases, a sural nerve biopsy will be unnecessary.
Management
Patients should be clinically monitored regularly for the development of neuropathic signs or symptoms, and the drug dose should be adjusted or discontinued as necessary.
Special considerations
Pregnancy
One study of the neurodevelopment of children exposed transplacentally to amiodarone suggested that there may be resultant learning disability (34).
Media
References
- 01
- Abarbanel JM, Osiman A, Frisher S, Herishanu Y. Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy. Isr J Med Sci 1987;23:893-5. PMID 2445709
- 02
- Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005;8:95-7. PMID 15860984
- 03
- Anderson NE, Lynch NM, O'Brien KP. Disabling neurologic complications of amiodarone. Aust NZ J Med 1985;15:300-4. PMID 3864421
- 04
- Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MN, editor. Myeler's side effects of drugs. 12th ed. Amsterdam: Elsevier, 1992:397-400.
- 05
- Bagchi D, Bagchi M, Stohs S, et al. Cellular protection with proantocyanidins derived from grape seeds. Ann N Y Acad Sci 2002;957:260-70. PMID 12074978
- 06
- Bagchi D, Ray SD, Patel D, Bagchi M. Protection against drug- and chemical-induced multiorgan toxicity by a novel IH636 grape seed proanthocyanidin extract. Drugs Exp Clin Res 2001;27:3-15. PMID 11276828
- 07
- Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-97. PMID 15449971
- 08
- Bayrakceken K, Ucgul RK, Coban T, Yazıcı G, Suleyman H. Effect of adenosine triphosphate on amiodarone-induced optic neuropathy in rats: biochemical and histopathological evaluation. Cutan Ocul Toxicol 2023;42(3):162-7. PMID 37335833
- 09
- Bockhardt H, Drenckhahn D, Lullmann-Rauch R. Amiodarone-induced lipidosis-like alterations in ocular tissues of rats. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1978;207:91-6. PMID 308785
- 10
- Borruat FX, Regli F. Pseudotumor cerebri as a complication of amiodarone therapy. Am J Ophthalmol 1993;116:776. PMID 8250090
- 11
- Carella F, Riva E, Morandi L, Cappiello E, Mangoni A. Myopathy during amiodarone treatment: a case report. Ital J Neurol Sci 1987;8:605-8. PMID 3429219
- 12
- Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984;34:669-71. PMID 6538658
- 13
- Chaubey VK, Chhabra L, Kapila A. Ataxia: a diagnostic perplexity and management dilemma. BMJ Case Rep 2013;2013. PMID 24072835
- 14
- Cheng HC, Yeh HJ, Huang N, Chou YJ, Yen MY, Wang AG. Amiodarone-associated optic neuropathy: a nationwide study. Ophthalmology 2015;122(12):2553-9. PMID 26391464
- 15
- Clem JR, Farver DK, Fischer JR, Johnson TJ. Dronedarone: a safety comparison to amiodarone. Curr Drug Saf 2010;5(3):251-6. PMID 20210734
- 16
- Clouston PD, Donnelly PE. Acute necrotizing myopathy associated with amiodarone therapy. Aust NZ J Med 1989;19:483-5. PMID 2590102
- 17
- Costa-Jussa FR, Guevara A, Brook GA, Duchen LW, Jacobs JM. Changes in denervated skeletal muscle of amiodarone-fed mice. Muscle Nerve 1988;11:627-37. PMID 3386672
- 18
- Costa-Jussa FR, Jacobs JM. The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. Brain 1985;108:735-52. PMID 2994808
- 19
- Feiner LA, Younge BR, Kazmier, Stricker BH, Fraunfelder FT. Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987;62:702-17. PMID 3600041
- 20
- Fernando Roth R, Itabashi H, Louie J, Anderson T, Narahara KA. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990;119:1223-5. PMID 2158741
- 21
- Flanagan EP, Harper CM, St Louis EK, Silber MH, Josephs KA. Amiodarone-associated neuromyopathy: a report of four cases. Eur J Neurol 2012;19(5):e50-1. PMID 22507462
- 22
- Fraser AG, McQueen IN, Watt AH, Stephens MR. Peripheral neuropathy during longterm high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry 1985;48:576-8. PMID 2989436
- 23
- Gurkov R, Manzari L, Blodow A, Wenzel A, Pavlovic D, Luis L. Amiodarone-associated bilateral vestibulopathy. Eur Arch Otorhinolaryngol 2018;275(3):823-5. PMID 29282523
- 24
- Ishida S, Sugino M, Hosokawa T, et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol 2010;29(2):84-8. PMID 20175957
- 25
- Jacobs JM, Costa-Jussa FR. The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man. Brain 1985;108:753-69. PMID 2994809
- 26
- Johnson LN, Krohel GB, Thomas ER. The clinical spectrum of amiodarone-associated optic neuropathy. J Natl Med Assoc 2004;96:1477-91. PMID 15586652
- 27
- Kaur P, Kaur A, Sinha A, Khaliq W, Dumic I, Singh A. Amiodarone-induced nystagmus and ataxia: case report and systematic review of case reports. J Clin Pharmacol 2023;63(12):1324-29. PMID 37571970
- 28
- Kervinen M, Falck A, Hurskainen M, Hautala N. Bilateral optic neuropathy and permanent visual loss after treatment with amiodarone. J Cardiovasc Pharmacol 2013;62(4):394-6. PMID 23921312
- 29
- Kodavanti PR, Pentlyala SN, Yallapragada R, Desaiah D. Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel. Naunyn Schmeidebergs Arch Pharmacol 1992;345(2):213-21. PMID 1314962
- 30
- Krauser DG, Segal AZ, Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol 2005;96:1463-4. PMID 16275201
- 31
- Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinet 1984;9:136-56. PMID 6370540
- 32
- Lemaire JF, Autret A, Biziere K, Romet-Lemone, Gray F. Amiodarone neuropathy: further arguments for human drug-induced neurolipidosis. Eur Neurol 1982;21:65-8. PMID 7094952
- 33
- Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999;127:610-2. PMID 10334361
- 34
- Magee LA, Nulman I, Rovet JF, Koren G. Neurodevelopment after in utero amiodarone exposure. Neurotoxicol Teratol 1999;21:261-5. PMID 10386829
- 35
- Manolis AS, Tordjman T, Mack KD, Estes NA 3d. Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. Arch Int Med 1987;147:1805-9. PMID 3310943
- 36
- Mansour AM, Puklin JE, O'Grady R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuroophthalmol 1988;8:231. PMID 2977138
- 37
- Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 2011;66(2):134-6. PMID 21630612
- 38
- Martinez-Arizala A, Sobol SM, McCarty GE, Nichols BR, Rakita L. Amiodarone neuropathy. Neurology 1983;33:643-5. PMID 6302557
- 39
- Meier C, Kauer B, Muller U, Ludin HP. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol 1979;220:231-9. PMID 90132
- 40
- Mitchell R, Chacko J. Clinical and mechanistic review of amiodarone-associated optic neuropathy. Biomolecules 2022;12(9):1298. PMID 36139137
- 41
- Nagra PK, Foroozan R, Savino PJ, et al. Amiodarone induced optic neuropathy. Br J Ophthalmol 2003;87:420-2. PMID 12642303
- 42
- Nazarian SM, Jay WM. Bilateral optic neuropathy associated with amiodarone therapy. J Clin Neuroophthalmol 1988;8:25-8. PMID 2972746
- 43
- Niimi N, Yako H, Tsukamoto M, et al. Involvement of oxidative stress and impaired lysosomal degradation in amiodarone-induced schwannopathy. Eur J Neurosci 2016;44(1):1723-33. PMID 27152884
- 44
- Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66:865-9. PMID 19597088
- 45
- Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Int Med 1987;147:881-4. PMID 3034178
- 46
- Passman RS, Bennett, Purpura JM, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med 2012;125:447-53. PMID 22385784
- 47
- Pellissier JF, Pouget J, Cros D, De Victor B, Serratrice G, Toga M. Peripheral neuropathy induced by amiodarone chlorohydrate. J Neurol Sci 1984;63:251-66. PMID 6323638
- 48
- Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromusc Dis 2002;3:97-105. PMID 19078662
- 49
- Rao KS, Fernando JC, Ho IK, Mehendale HM. Neurotoxicity in rats following subchronic amiodarone treatment. Res Commun Chem Pathol Pharmacol 1986a;52:217-24. PMID 3715200
- 50
- Rao KS, Rao SB, Camus PH, Mehendale HM. Effect of amiodarone on Na+-, K+-ATPase and Mg2+-ATPase activities in rat brain synaptosomes. Cell Biochem Funct 1986b;4:143-51. PMID 2423267
- 51
- Reasor MJ, Ogle CL, Walker ER, Kacew S. Amiodarone-induced phospholipidosis in rat alveolar macrophages. Am Rev Respir Dis 1988;137:510-8. PMID 2830811
- 52
- Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006;40:753-7. PMID 16537817
- 53
- Roden DM. Antiarrhythmic drugs. In: Goodman LS, Gilman A, editors. The pharmacologic basis of therapeutics. 9th ed. New York: Pergamon, 1996:858-862.
- 54
- Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004;38:978-81. PMID 15069169
- 55
- Saha SA. Severe muscle cramps after intravenous administration of amiodarone – a novel, potentially dose-dependent adverse effect. Br J Clin Pharmacol 2011;71(4):624-5. PMID 21395658
- 56
- Santoro L, Barbieri F, Nucciotti R, et al. Amiodarone-induced experimental acute neuropathy in rats. Muscle Nerve 1992;15:788-95. PMID 1323756
- 57
- Tan Y, Sia P, Simon S. Optic neuropathy secondary to perhexiline and amiodarone. BMJ Case Rep 2021;14(1):e237727. PMID 33504523
- 58
- Vrobel TR, Miller PE, Mostow ND, Rakita L. A general overview of amiodarone toxicity: Its prevention, detection, and management. Prog Cardiovasc Dis 1989;31:393-426. PMID 2652188
- 59
- Wang AG, Cheng HC. Amiodarone-associated optic neuropathy: clinical review. Neuroophthalmology 2016;41(2):55-8. PMID 28348626
- 60
- Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Neurology 1989;25:630-2. PMID 2742365
- 61
- Witkowski M, Mochmann HC, Rauch U, Knie W, Landmesser U, Skurk C. Acute thrombotic occlusion of the left brachial artery after intra-arterial administration of amiodarone. Crit Care Med 2016;44(4):e227-30. PMID 26571183
- 62
- Wu C, Tcherny-Lessenot S, Dai W, et al. Assessing the risk for peripheral neuropathy in patients treated with dronedarone compared with that in other antiarrhythmics. Clin Ther 2018;40(3):450-5.e1. PMID 29500139
- 63
- Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935-41. PMID 17329700
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Steven Herskovitz MD
Dr. Herskovitz of Montefiore Medical Center, Albert Einstein College of Medicine, has no relevant financial relationships to disclose.
See Profile
Editor
-
Louis H Weimer MD
Dr. Weimer of Columbia University received a consultant honorarium from Roche and Ovid Therapeutics.
See Profile
Patient Profile
- Age range of presentation
-
- 0 months to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- none
- Population groups selectively affected
-
- None selectively affected
- Occupation groups selectively affected
-
- None selectively affected
ICD & OMIM codes
- ICD-10
-
- Drug-induced polyneuropathy: G62.0
- ICD-11
-
- Drug-induced polyneuropathy: 8D43.20
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Peripheral Neuropathies
Toxic peripheral neuropathies
Jun. 11, 2026
-
Peripheral Neuropathies
Organophosphate neuropathy
Jun. 11, 2026
-
Peripheral Neuropathies
Diphtheritic neuropathy
May. 12, 2026
-
Neuromuscular Disorders
Efgartigimod alfa and hyaluronidase-qvfc
Apr. 23, 2026
-
Peripheral Neuropathies
Acrylamide neuropathy
Apr. 09, 2026
-
Infectious Disorders
Whipple disease
Apr. 08, 2026
-
Peripheral Neuropathies
Neurolymphomatosis
Apr. 07, 2026